These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2482549)

  • 1. The influence of Org 10172, an antithrombotic heparinoid, on urinary blood loss after transurethral prostatectomy.
    Gallus A; Murphy W; Nacey J; Morris M; Sutherland P; Marshall V; Magnani H
    Thromb Res; 1989 Oct; 56(2):229-38. PubMed ID: 2482549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orgaran (Org 10172) or heparin for preventing venous thrombosis after elective surgery for malignant disease? A double-blind, randomised, multicentre comparison. ANZ-Organon Investigators' Group.
    Gallus A; Cade J; Ockelford P; Hepburn S; Maas M; Magnani H; Bucknall T; Stevens J; Porteous F
    Thromb Haemost; 1993 Oct; 70(4):562-7. PubMed ID: 7509509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized double-blind, placebo controlled safety study of a low molecular weight heparinoid in patients undergoing transurethral resection of the prostate.
    ten Cate H; Henny CP; ten Cate JW; Büller HR; Dabhoiwala NF
    Thromb Haemost; 1987 Feb; 57(1):92-6. PubMed ID: 2438799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-molecular-weight heparinoid compared with warfarin for prophylaxis of deep-vein thrombosis in patients who are operated on for fracture of the hip. A prospective, randomized trial.
    Gerhart TN; Yett HS; Robertson LK; Lee MA; Smith M; Salzman EW
    J Bone Joint Surg Am; 1991 Apr; 73(4):494-502. PubMed ID: 1707413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke.
    Turpie AG; Levine MN; Hirsh J; Carter CJ; Jay RM; Powers PJ; Andrew M; Magnani HN; Hull RD; Gent M
    Lancet; 1987 Mar; 1(8532):523-6. PubMed ID: 2434815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. A randomized, double-blind study.
    Turpie AG; Gent M; Côte R; Levine MN; Ginsberg JS; Powers PJ; Leclerc J; Geerts W; Jay R; Neemeh J
    Ann Intern Med; 1992 Sep; 117(5):353-7. PubMed ID: 1503326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of deep vein thrombosis following total hip replacement by low molecular weight heparinoid.
    Hoek JA; Nurmohamed MT; Hamelynck KJ; Marti RK; Knipscheer HC; ten Cate H; Büller HR; Magnani HN; ten Cate JW
    Thromb Haemost; 1992 Jan; 67(1):28-32. PubMed ID: 1615479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early clinical experience of a new heparinoid, Org 10172, in prevention of deep venous thrombosis.
    Cade JF; Wood M; Magnani HN; Westlake GW
    Thromb Res; 1987 Mar; 45(5):497-503. PubMed ID: 3590088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators.
    JAMA; 1998 Apr 22-29; 279(16):1265-72. PubMed ID: 9565006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies of Org 10172 in patients with acute ischemic stroke. TOAST Study Group.
    Adams HP; Woolson RF; Biller J; Clarke W
    Haemostasis; 1992; 22(2):99-103. PubMed ID: 1379970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel anti-thrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity: a survey of its pharmacological properties in experimental animal models.
    Meuleman DG; Hobbelen PM; van Dedem G; Moelker HC
    Thromb Res; 1982 Aug; 27(3):353-63. PubMed ID: 6182627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dose escalation study of ORG 10172 (low molecular weight heparinoid) in stroke.
    Biller J; Massey EW; Marler JR; Adams HP; Davis JN; Bruno A; Henriksen RA; Linhardt RJ; Goldstein LB; Alberts M
    Neurology; 1989 Feb; 39(2 Pt 1):262-5. PubMed ID: 2464774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orgaran in the prevention of deep vein thrombosis in stroke patients.
    Turpie AG
    Haemostasis; 1992; 22(2):92-8. PubMed ID: 1379969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orgaran in hip fracture surgery.
    Bergqvist D
    Haemostasis; 1992; 22(2):104-8. PubMed ID: 1379963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrointestinal blood loss in haemodialysis patients during use of a low-molecular-weight heparinoid anticoagulant.
    Frei U; Wilks MF; Boehmer S; Crisp-Lindgren N; Schwarzrock R; Stiekema JC; Koch KM
    Nephrol Dial Transplant; 1988; 3(4):435-9. PubMed ID: 2459635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers.
    Stiekema JC; Wijnand HP; Van Dinther TG; Moelker HC; Dawes J; Vinchenzo A; Toeberich H
    Br J Clin Pharmacol; 1989 Jan; 27(1):39-48. PubMed ID: 2468354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synopsis of the anticoagulant and antithrombotic profile of the low molecular weight heparinoid Org 10172 in experimental models.
    Meuleman DG
    Semin Thromb Hemost; 1989 Oct; 15(4):370-2. PubMed ID: 2479103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction study between Org 10172, a low molecular weight heparinoid, and acetylsalicylic acid in healthy male volunteers.
    de Boer A; Danhof M; Cohen AF; Magnani HN; Breimer DD
    Thromb Haemost; 1991 Aug; 66(2):202-7. PubMed ID: 1722918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "Heparin-free" cardiopulmonary bypass: first reported use of heparinoid (Org 10172) to provide anticoagulation for cardiopulmonary bypass.
    Doherty DC; Ortel TL; de Bruijn N; Greenberg CS; Van Trigt P
    Anesthesiology; 1990 Sep; 73(3):562-5. PubMed ID: 1697448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thromboembolic prophylaxis in total hip replacement: a comparison between the low molecular weight heparinoid Lomoparan and heparin-dihydroergotamine.
    Leyvraz P; Bachmann F; Bohnet J; Breyer HG; Estoppey D; Haas S; Hochreiter J; Jakubek H; Mair J; Sorensen R
    Br J Surg; 1992 Sep; 79(9):911-4. PubMed ID: 1422754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.